Iseganan HCl: a novel antimicrobial agent (Q34768583)

4 August 2017

1 reference

title

Iseganan HCl: a novel antimicrobial agent (English)

1 reference

4 August 2017

Francis J Giles

1

1 reference

4 August 2017

Rebecca Redman

series ordinal

2

1 reference

4 August 2017

Salim Yazji

series ordinal

3

1 reference

4 August 2017

Lisa Bellm

series ordinal

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

1 reference

4 August 2017

11

1 reference

4 August 2017

8

1 reference

4 August 2017

1161-1170

1 reference

Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity.

4 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Oral mucositis in myelosuppressive cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Toxicity in head and neck cancer: a review of trends and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Quality of life and oral function in patients treated with radiation therapy for head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Oral health and quality of life among patients with head and neck cancer or haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Epithelial antimicrobial peptides: review and significance for oral applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Protegrins: new antibiotics of mammalian origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Oral sources of septicaemia in patients with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Stomatotoxic manifestations of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Nosocomial pneumonia. Diagnosis and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Pilot trial of selective decontamination for prevention of bacterial infection in an intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

The prevention of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.8.1161

10.1517/13543784.11.8.1161

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference